Amphastar Pharmaceuticals

Historical price data

Amphastar Pharmaceuticals is a vertically integrated biopharmaceutical company with a core mission to develop and deliver high-quality, complex generic and proprietary injectable, inhalation, and intranasal medications. The company has established a strong commercial footprint with products like BAQSIMI®, the leading prescribed glucagon in the U.S., and has been recognized by the FDA for its efforts in alleviating critical drug shortages. Its strategic direction leverages proprietary technological platforms to advance a pipeline of biosimilars and innovative drug delivery systems, aiming to provide accessible treatments across therapeutic areas such as diabetes, respiratory diseases, and anemia.

Proprietary platforms for dry powder nasal delivery, metered-dose inhalation (MDI), complex injectable formulations (including biologics and biosimilars), and prefilled delivery systems, enabling development of high-barrier-to-entry generic and proprietary drugs.

Amphastar competes with large generic firms (Teva, Viatris), specialty pharma (Vifor), and biotech (Xeris) across its product segments. Its differentiation stems from vertical integration, expertise in complex delivery systems (nasal, inhalation), and a proven track record in mitigating drug shortages, which builds trust with healthcare systems.